NVO
NOVO NORDISK A S
Healthcare • CIK 0000353278
Loading...
Market Cap
—
P/E (TTM)
—
Rev Growth (TTM)
—
Net Margin (TTM)
—
FCF Yield (TTM)
—
FCF Margin (TTM)
—
Filings
Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.
6-KJul 20262026-07-06source
6-KJun 20262026-06-24source
6-KJun 20262026-06-15source
6-KJun 20262026-06-08source
6-KJun 20262026-06-01source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
Company-published, not SEC-audited
Earnings
No earnings in last 90 days
Check back after next 8-K filing
Most recent quarterly earnings snapshot
Filing Changes
340B Drug Pricing Program Riskhigh (USD 4.2B revenue constrained as provision for...→low (HRSA dismissed ADR petition January 20, 2026; USD...
US GLP-1 and Insulin Net Pricesmedium (US payer rebate pressure increasing in insulin...→medium (average net prices after rebates for full Novo...
GLP-1 Volume Market Sharemedium (competitive pressure emerging in both obesity...→medium (volume market share lost in GLP-1 for both...
Akero Therapeutics Acquisitionno MASH clinical-stage asset in pipeline→acquired Akero Therapeutics at $54 per share (Phase 3...
Illicit GLP-1 Compoundingmedium (GLP-1 drug shortage permitting compounding...→medium (GLP-1 shortage resolved but illicit compounding...
20-F FY 2025 vs 20-F FY 2024
Cash Flow Health
Free Cash Flow0/8 positive
TTM$–
FCF Margin
TTM–
Sector: 0.0%
OCF Margin–
OCF/NI–
CapEx Coverage–
FCF Yield–
FCF Growth (2Y)–
Cash Conversion Cycle
–
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder Yield
TTM22.9%
Dividend & Payout Metrics
Dividend Yield (TTM)—
Buyback data not disclosed in this company's filings.
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
–
Valuation Lenses
Earnings
–
vs – sector
Cash Flow
–
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: –
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap–
EV–
Multi-angle valuation analysis with sector context
Margins & Efficiency
Profitability Cascade
Gross
—
Operating
—
Net
—
Margins Unknown
Return on Invested CapitalTTM
—
P25MedianP75
(med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
—
Asset Turnover
–
Leverage (1+D/E)
1.67x
D/E: 0.67x
Asset & CapEx Efficiency
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
D/E 0.67x
Net Debt / EBITDA
–Net Debt: $104.49B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.67x
Balance sheet risk & solvency analysis
Related Research
1 related post